- 1. An isolated nucleic acid molecule comprising a nucleotide sequence:
  - (a) as set forth in SEQ ID NO: 1;
  - (b) encoding a polypeptide as set forth in SEQ ID NO: 2; or
  - (c) that is complementary to the nucleotide sequence of either (a) or (b).
- 2. An isolated nucleic acid molecule comprising a nucleotide sequence:
  - (a) as set forth in SEQ ID NO: 1;
  - (b) encoding a polypeptide as set forth in SEQ ID NO: 2;
  - (c) that hybridizes to the complement of the nucleotide sequence of either (a) or (b) under hybridization conditions allowing no more than a 21% mismatch between the nucleotide sequences; or
  - (d) that is complementary to the nucleotide sequence of any of (a) (c).
- 3. An isolated nucleic acid molecule comprising:
  - (a) a region of the nucleotide sequence of SEQ ID NO: 1 encoding a polypeptide fragment of at least 25 amino acid residues;
  - (b) a region of the nucleotide sequence of SEQ ID NO: 1 comprising a fragment of at least 16 nucleotides;
  - (c) a nucleotide sequence that hybridizes to the complement of the nucleotide sequence of either (a) or (b) under hybridization conditions allowing no more than a 21% mismatch between the nucleotide sequences; or
  - (d) a nucleotide sequence that is complementary to the nucleotide sequence of any of(a) (c).
- 4. An isolated nucleic acid molecule comprising:
  - (a) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 2 with at least one conservative amino acid substitution, wherein the encoded polypeptide is at least 70 percent identical to the polypeptide set forth in SEQ ID NO: 2;

4

- (b) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 2 having a C- and/or N- terminal truncation, wherein the encoded polypeptide comprises at least 25 amino acid residues;
- (c) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 2 with at least one modification that is a conservative amino acid substitution, C-terminal truncation, or N-terminal truncation, wherein the encoded polypeptide is at least 70 percent identical to the polypeptide set forth in SEQ ID NO: 2 and comprises at least 25 amino acid residues;
- (d) a region of the nucleotide sequence of any of (a) (c) comprising a fragment of at least 16 nucleotides;
- (e) a nucleotide sequence that hybridizes to the complement of the nucleotide sequence of any one of (a) (d) under hybridization conditions allowing no more than a 21% mismatch between the nucleotide sequences; or
- (f) a nucleotide sequence that is complementary to the nucleotide sequence of any of (a) (e).
- 5. A vector comprising the nucleic acid molecule of any of Claims 1, 2, 3, or 4.
- 6. A host cell comprising the vector of Claim 5.
- 7. The host cell of Claim 6 that is a eukaryotic cell.
- 8. The host cell of Claim 6 that is a prokaryotic cell. 4
- 9. A process of producing an IL-1ra-L polypeptide comprising culturing the host cell of Claim 6 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.

## BEST AVAILABLE COPY

61

10. The process of Claim 9, wherein the nucleic acid molecule comprises promoter DNA other than native IL-1ra-L promoter DNA operatively linked to a nucleic acid molecule encoding an IL-1ra-L polypeptide.

4

4

. (

- 11. The isolated nucleic acid molecule according to Claim 4, wherein the percent identity is determined using a computer program that is GAP, BLASTN, FASTA, BLASTX, BestFit, or the Smith-Waterman algorithm.
- 12. A composition comprising a nucleic acid molecule of any of Claims 1, 2, 3, or 4 and a pharmaceutically acceptable formulation agent.
- 13. The composition of Claim 12, wherein said nucleic acid molecule is contained in a viral vector.
- 14. A viral vector comprising a nucleic acid molecule of any of Claims 1, 2, 3, or 4.
- 15. A nucleic acid molecule encoding a fusion polypeptide comprising the nucleic acid molecule of any of Claims 1, 2, 3, or 4 fused to DNA encoding a heterologous amino acid sequence.
- 16. The nucleic acid molecule of Claim 15, wherein the DNA encoding the heterologous amino acid sequence encodes an IgG constant domain or biologically active fragment thereof.